Blog
RSS FeedPosted by Michael Wonder on 01 Mar 2016
Fingolimod in multiple sclerosis: no evidence of additional benefits in the new application
1 March 2016 - This assessement was about patients with highly active relapsing-remitting multiple sclerosis, on a full and adequate course ...
Posted by Michael Wonder on 01 Mar 2016
Aflibercept in myopic choroidal neovascularisation: additional benefits not covered
1 March 2016 - Since the manufacturer provides no adequate studies, an additional benefit of aflibercept versus the appropriate comparator therapy ...
Posted by Michael Wonder on 15 Feb 2016
Alirocumab hypercholesterolemia or mixed dyslipidaemia: additional benefits not covered says IQWiG
15 February 2016 - An additional benefit compared to the appropriate comparator therapies has not been established for this substance because ...
Posted by Michael Wonder on 16 Jan 2016
Aclidinium bromide in COPD: evidence of significant additional value in certain patients
15 January 2016 - With reference to new scientific evidence, the manufacturer requested a reassessment and submitted a new dossier. ...
Posted by Michael Wonder on 14 Jan 2016
Regorafenib in metastatic colorectal cancer: still only a hint of a minor additional benefit
4 January 2016 - After the expiry of the decision it made in 2014, the IQWIG has the reached same ...
Posted by Michael Wonder on 13 Jan 2016
Nivolumab in melanoma: data subsequently submitted improve assessment result
7 January 2016 - In an addendum, the IQWiG assessed study data submitted by BMS. In treatment-naive patients whose tumour is ...
Posted by Michael Wonder on 12 Jan 2016
Pomalidomide in multiple myeloma: no sign of an additional clinical benefit
4 January 2016 - The IQWiG examined whether pomalidomide offers an added benefit over the appropriate comparator therapy. No such added ...
Posted by Michael Wonder on 12 Jan 2016
Dabrafenib in combination with trametinib in advanced melanoma with BRAF V600 mutation: indication of added benefit says IQWiG
4 January 2016 - According to the findings, no added benefit is proven for trametinib monotherapy because of a lack of ...
Posted by Michael Wonder on 05 Jan 2016
IQWIG Autumn Symposium 2015: presentations now online
5 January 2016 - Real world data: a gain for benefit assessments? This question was the focus of the Autumn Symposium ...
Posted by Michael Wonder on 22 Dec 2015
Evolocumab: no hint of added clinical benefit according the IQWiG in Germany
15 December 2015 - The dossier contained no suitable data for hypercholesterolaemia or for mixed dyslipidaemia. ...
Posted by Michael Wonder on 15 Dec 2015
Evolocumab: no evidence of additional clinical benefits says IQWiG
15 December 2015 - The dossier did not contain appropriate data for patients with hypercholesterolaemia nor for mixed dyslipidaemia. ...
Posted by Michael Wonder on 04 Dec 2015
Neo-adjuvant use of pertuzumab in HER2-positive breast cancer: hint of lesser benefit
1 December 2015 - In a further dossier assessment, the IQWiG has examined the benefit of pertuzumab in its second therapeutic ...
Posted by Michael Wonder on 04 Dec 2015
Secukinumab in psoriasis: now an indication of an additional clinical benefit for certain patients
30 November 2015 - The extent of the additional clinical benefit varies by the type of prior therapy, however: It is ...
Posted by Michael Wonder on 25 Nov 2015
Netupitant with palonosetron hydrochloride for the prevention of nausea and vomiting: added benefit not proven says IQWiG
16 November 2015 - According to the findings, an added clinical benefit is not proven in moderately emetogenic or in highly ...
Posted by Michael Wonder on 23 Nov 2015
Pembrolizumab in advanced melanoma: additional clinical benefit for certain patients says German IQWiG
16 November 2015 - According to the findings, an additional clinical benefit can be derived for different patient groups: in pretreated ...